MedTrace Logo

EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

NCT02648035 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-03-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the percentage of participants treated with subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that play a major role in continuation of treatment.

Conditions

Interventions

BIOLOGICAL

Tocilizumab

Subcutaneous Tocilizumab according to approved label.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-22
Primary Completion
2018-12-20
Completion
2018-12-20

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648035 on ClinicalTrials.gov